Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 15

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 15
---
 >$950M in product revenue from 2020 to 2022 P Disciplined Capital Returns: Announced authorization of $200M share repurchase program in November 2024 P Strengthened Accountability: Proactively refreshed the Board, with 6 of 8 independent directors at the 2025 annual meeting appointed since 2020. We are also implementing a phased board declassification to further bolster accountability to stockholders The Dynavax Board Has Delivered for Stockholders 20 | Since the strategic pivot, the Board has overseen: © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 2019 2020 2021 2022 2023 2024 2025 Ryan Spencer Brent MacGregor Peter Paradiso Scott Myers Elaine Sun Emilio Emini Lauren Silvernail Daniel Kisner Francis Cano 

# of Director Retirements Each Year – – – – Board Size Post - AGM 8 7 9 11 10 9 9 Proactive Board Refreshment Has Been Key to Our Success 21 | Since 2020, the Board has strategically refreshed 75% of its independent directors , ensuring Dynavax has the right mix of skillsets and experiences to sustain its trajectory © Copyright DYNAVAX 2025
ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Daniel Kisner Compensation Committee Lauren Silvernail • 30+ years of experience leading finance, commercialization, and business development functions across the biomedical and pharmaceutical industries as an executive and director • Deep expertise across capital markets, mergers and acquisitions, and business and strategy development Brent MacGregor • ~25 years of commercial experience in the vaccine industry spanning continents, including as Global Head of Novartis Influenza Vaccines and SVP, Global Commercial Operations of Seqirus • Extensive experience in commercial operations, sales and marketing, public policy, business development, and capital markets Emilio Emini, Ph.D. • 40+ years of executive